Search
Relmada Therapeutics Inc
RLMDAdd to Watchlist
6.570USD
+0.200+3.14%
Close 06/16, 16:00（ET）Quotes delayed by 15 min
687.03MMarket Cap
LossP/E TTM
Risk Assessment
Currency: USD Updated: 2026-06-16The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Relmada Therapeutics Inc is 1.94, ranking 253 out of 388 in the Biotechnology & Medical Research industry. The company's beta value is 0.40. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Beta vs S&P 500 index
0.40
VaR
+7.37%
240-Day Maximum Drawdown
+27.44%
240-Day Volatility
+123.10%
Return
Best Daily Return
60 days
+10.88%
120 days
+61.12%
5 years
+82.54%
Worst Daily Return
60 days
-8.12%
120 days
-9.52%
5 years
-79.57%
Sharpe Ratio
60 days
+0.61
120 days
+1.22
5 years
+0.50
Risk Assessment
Maximum Drawdown
240 days
+27.44%
3 years
+96.30%
5 years
+99.32%
Return-to-Drawdown Ratio
240 days
+36.06
3 years
+0.54
5 years
-0.15
Skewness
240 days
+3.25
3 years
+0.94
5 years
-0.37
Volatility
Realised Volatility
240 days
+123.10%
5 years
+146.15%
Standardised True Range
240 days
+5.26%
5 years
+8.84%
Downside Risk-Adjusted Return
120 days
+390.49%
240 days
+390.49%
Maximum Daily Upside Volatility
60 days
+47.24%
Maximum Daily Downside Volatility
60 days
+41.63%
Liquidity
Average Turnover Rate
60 days
+3.70%
120 days
+3.96%
5 years
--
Turnover Deviation
20 days
+10.83%
60 days
+11.58%
120 days
+19.58%
